Is Wall Street Bullish or Bearish on STERIS Stock?
STERIS plc (STE) has outperformed the broader S&P 500 index over the past 52 weeks but recently faced a selloff following a Q3 revenue beat that was overshadowed by margin pressure and tariff headwinds. Despite management warning of a second-half slowdown, Wall Street maintains a "Moderate Buy" consensus with a mean price target suggesting significant upside.
Is Wall Street Bullish or Bearish on STERIS Stock?
STERIS plc (STE) has outperformed the broader S&P 500 and the Health Care Select Sector SPDR ETF over the past 52 weeks, despite a recent 7.7% dip after Q3 2026 earnings due to a Q4 slowdown warning and tariff headwinds. Analysts maintain a "Moderate Buy" rating, with a mean price target suggesting a 14.8% upside from current levels, indicating a generally bullish outlook despite short-term challenges.
Waste Management and Remediation Services Industry Report
The waste management and remediation services market is projected to reach $1.14 trillion by 2030, growing from $819.26 billion in 2025 at a CAGR of 7%. Key growth drivers include stringent regulations, circular economy investments, smart waste technologies, and rising demand for environmental cleanup, particularly for hazardous waste and PFAS solutions. Strategic acquisitions and technological innovations, like Crystal Clean's SAFF10 for PFAS remediation, are further shaping the market, with Western Europe and Asia-Pacific being significant growth regions.
$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices
The global market for Negative Pressure Wound Therapy (NPWT) devices is projected to grow from $2.9 billion in 2025 to $3.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This growth is driven by the increasing demand for advanced wound healing technologies, particularly for managing diabetic foot ulcers and surgical site infections. The report analyzes market trends, applications, end-users, and regional dynamics, profiling major companies such as Solventum and Smith+Nephew.
Maridea Wealth Management LLC Purchases New Position in STERIS plc $STE
Maridea Wealth Management LLC initiated a new position in STERIS plc (NYSE:STE) during the third quarter, acquiring 4,885 shares valued at approximately $1,183,000. Institutional investors now hold about 94.69% of the company's stock. STERIS recently reported quarterly earnings in line with estimates, with revenue up 9.2% year-over-year, and declared a quarterly dividend of $0.63 per share.
Pallas Capital Advisors LLC Buys New Position in STERIS plc $STE
Pallas Capital Advisors LLC has acquired a new stake of 4,467 shares in STERIS plc, valued at approximately $1,105,000, during the third quarter. This investment is part of a broader trend of institutional investors modifying their holdings in STERIS, with other firms like Norges Bank and Orbis Allan Gray Ltd also significantly increasing their stakes. Analyst ratings for STERIS currently average a "Moderate Buy" with a consensus price target of $275.20, and the company recently declared a quarterly dividend of $0.63 per share.
STERIS plc (NYSE:STE) Sees Large Growth in Short Interest
Short interest in STERIS plc (NYSE:STE) increased by 22.7% in January, totaling 1,560,494 shares, which equates to 1.6% of the company's stock being sold short. Despite increased bearish sentiment, STERIS's Q4 earnings met expectations with $2.53 EPS and a 9.2% revenue increase year-over-year, and the company issued optimistic FY2026 guidance. STERIS also declared a quarterly dividend of $0.63 per share, representing an annualized yield of about 1.0%.
STERIS plc (STE) Remains in Focus as Analysts Reaffirm Confidence
STERIS plc (STE) is attracting renewed analyst confidence after strong Q3 FY2026 financial results. Citizens reiterated its "Market Outperform" rating with a $280 price target, following STERIS beating revenue expectations and matching profit forecasts. The company's organic revenue growth and reaffirmed full-year guidance suggest a robust position in the medical technology sector, despite expected tariff impacts.
The Bull Case For STERIS (STE) Could Change Following Margin Pressures Amid Revenue Growth And Buybacks
STERIS (STE) recently reported strong Q3 2025 results with increased sales and net income, alongside a significant share repurchase program. However, the company faces ongoing margin pressures due to tariffs and inflation, which could impact its future profitability despite its consistent revenue growth driven by demand for infection prevention and sterilization. Investors are weighing these cost headwinds against the company's solid growth and historical performance.
10 Best Medical Technology Stocks to Invest In
This article identifies STERIS plc (NYSE:STE) as one of the best medical technology stocks to invest in, highlighting its strong financial performance. The company exceeded revenue expectations and matched profit forecasts for Q3 FY2026, demonstrating robust growth driven by demand across multiple business lines. Analysts maintain a "Market Outperform" rating with a $280 price target, recognizing STERIS's strong position in the medical technology sector.
10 Best Medical Technology Stocks to Invest In
This article highlights STERIS plc (NYSE: STE) as one of the best medical technology stocks to invest in, noting its strong Q3 FY2026 financial results. STERIS exceeded revenue expectations and matched profit forecasts, demonstrating significant year-over-year growth and reaffirming its full-year guidance. The company, which specializes in infection prevention and procedural support, showcased robust organic revenue growth driven by demand across various business lines.
The Bull Case For STERIS (STE) Could Change Following Margin Pressures Amid Revenue Growth And Buybacks
STERIS (STE) recently reported increased sales of US$1,496.2 million and net income of US$192.9 million, alongside a US$350.6 million share repurchase. While the company exhibits strong revenue growth and profitability, it faces ongoing margin pressures due to tariffs and inflation. This tension between rising earnings and increasing costs could impact its investment narrative, especially concerning future earnings resilience and valuation.
Ex-Dividend Reminder: STERIS, Assurant and Kemper
STERIS plc (STE), Assurant Inc (AIZ), and Kemper Corp (KMPR) are scheduled to trade ex-dividend on February 17, 2026, for their upcoming quarterly dividends. Shares of each company are expected to open lower by 0.26%, 0.41%, and 0.99% respectively, all else being equal. Investors are advised to review dividend histories to assess the stability and potential continuation of these payouts.
Krilogy Financial LLC Buys New Stake in STERIS plc $STE
Krilogy Financial LLC has acquired a new position in STERIS plc (NYSE:STE), purchasing 4,847 shares valued at approximately $1,179,000 during the 3rd quarter. Other institutional investors also adjusted their holdings in STERIS, which saw its stock trade up by 0.5% at market opening and reported solid earnings, hitting analyst consensus estimates. The company has also declared a quarterly dividend of $0.63 per share.
Wall Street Has a Positive Opinion on PROCEPT BioRobotics (PRCT), Here's Why
Wall Street analysts are optimistic about PROCEPT BioRobotics (PRCT) ahead of its Q4 2025 earnings report, with expectations for strong revenue and GAAP EPS. Despite one analyst maintaining a Hold rating, the majority hold Buy ratings, and the average price target suggests significant upside. The company specializes in surgical robotics for urology with its AquaBeam Robotic System.
The Truth About STERIS plc (STE): Quiet Hospital Giant, Loud Stock Moves – Worth Your Money or Nah
STERIS plc (STE) is a major player in medical sterilization and surgical support, essential for hospitals and healthcare facilities. Despite not being a flashy consumer brand, its stock is considered stable due to the constant demand for healthcare services and the ingrained nature of its products in hospital workflows. The article suggests that while it may not offer quick gains like meme stocks, STERIS plc is a solid long-term investment for those seeking reliability in their portfolio.
The Truth About STERIS plc (STE): Quiet Hospital Giant, Loud Stock Moves – Worth Your Money or Nah
The article analyzes STERIS plc (STE), a low-key medical equipment giant specializing in sterilization and infection prevention. It highlights the company's strong position in the healthcare infrastructure due to consistent demand and a "lock-in" business model, despite not generating viral social media hype. The piece concludes that STE is a "cautious cop" for long-term, diversified portfolios, ideal for investors seeking stability rather than short-term gains, despite regulatory and competitive risks.
STERIS Restructuring And Deals Test Earnings Strength And Dividend Resolve
STERIS (NYSE:STE) is undertaking restructuring and strategic acquisitions to adapt to a changing medical technology landscape, driven by regulatory shifts and inflationary pressures. Despite a recent stock decline, the company reported higher sales and net income in the third quarter and for the nine-month period, maintaining a quarterly dividend of $0.63 per share. Investors will be watching how effectively STERIS integrates new businesses and manages operational costs, especially concerning potential impacts on margins and long-term profitability amidst ongoing market changes.
The 5 Most Interesting Analyst Questions From STERIS's Q4 Earnings Call
STERIS (STE) Q4 FY2025 results received a negative market reaction despite beating revenue estimates and meeting EPS consensus, with management citing broad-based volume growth but also margin pressures from tariffs and inflation. The article highlights key questions from analysts during the earnings call, focusing on growth rates, customer demand, tariff impacts, regulatory shifts, and acquisition strategy. Analysts will be monitoring tariff mitigation, healthcare demand, life sciences momentum, cost control, and regulatory navigation in upcoming quarters.
STERIS Restructuring And Deals Test Earnings Strength And Dividend Resolve
STERIS (NYSE:STE) is undergoing restructuring and making strategic acquisitions to adapt to the evolving medical technology and sterilization sectors. These efforts aim to enhance operational flexibility and reinforce its market position, with investors closely watching execution and integration. Despite significant corporate changes, STERIS continues to report strong sales and earnings, maintaining its quarterly dividend, suggesting a balanced approach to growth and shareholder returns.
Dental Impression Systems Market Size, Share | Forecast [2034]
The global dental impression systems market, valued at USD 1.85 billion in 2025, is projected to reach USD 3.30 billion by 2034, growing at a CAGR of 6.7%. This growth is driven by increasing demand for dental treatments, technological advancements, and a significant shift from traditional to digital impression systems. Key market players like Dentsply Sirona and Align Technology are focusing on innovation and strategic partnerships to capitalize on these opportunities.
Steris Reshapes Portfolio Around Healthcare And AST As Shares Lag Target
STERIS (NYSE:STE) is restructuring its operations, integrating recent acquisitions, and focusing on its Healthcare and AST segments which are showing growth. These strategic moves aim to refine the company's operating model within medical equipment and sterilization services. Investors should monitor the impact on margins, capital allocation, and competitive positioning, especially as the stock currently trades about 13% below analyst targets, indicating potential for close observation regarding execution and efficiency gains.
The Cooper Companies (COO) Moved Higher as Multiple Tailwinds Align
The Cooper Companies (COO) was highlighted as a top contributor in Sustainable Growth Advisers' (SGA) Q4 2025 investor letter. The company demonstrated strong operating results by alleviating supply constraints, securing new contracts, and driving innovation in its medical device segments. Shareholder-friendly developments, such as revised management compensation incentives and strategic review of its women's health business, also contributed to positive sentiment, leading SGA to maintain an average weight in COO after trimming some of its position.
What To Expect From Zimmer Biomet's (ZBH) Q4 Earnings
Zimmer Biomet (ZBH) is set to announce its Q4 earnings, with analysts expecting revenue growth of 9.9% year-on-year to $2.22 billion and adjusted earnings of $2.40 per share. The company has a history of meeting or slightly exceeding revenue estimates. Peers in the healthcare equipment sector have shown mixed results, with some underperforming recently due to economic stability concerns.
Savant Capital LLC Has $2.53 Million Position in STERIS plc $STE
Savant Capital LLC significantly increased its stake in STERIS plc (NYSE:STE) by 97.1% during the third quarter, now holding 10,215 shares valued at approximately $2.53 million. This comes as STERIS reported strong quarterly earnings in line with estimates and provided optimistic FY2026 EPS guidance, maintaining a "Moderate Buy" consensus among analysts. Despite recent insider selling, institutional investors own a substantial 94.69% of the company, which also offers a quarterly dividend.
STERIS plc $STE Holdings Decreased by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. has reduced its holdings in STERIS plc by 9.8% in Q3, now owning 359,197 shares valued at $88.88 million. Despite this, institutional investors collectively own 94.69% of the company's stock. STERIS reported strong Q3 results, meeting EPS estimates and exceeding revenue expectations, and provided optimistic FY2026 guidance, while insiders have recently sold shares worth approximately $6.59 million.
Is STERIS stock outperforming the S&P 500?
The article analyzes whether STERIS plc (STE) stock is outperforming the S&P 500 based on its recent price performance. It highlights STERIS's year-to-date return of 4.54% compared to the S&P 500's 2.91%, suggesting that STE stock is indeed outperforming the broader market during this period. The piece concludes by noting that while short-term outperformance is a positive indicator, investors should not rely solely on it for long-term decisions.
Allianz Asset Management GmbH Acquires 13,553 Shares of STERIS plc $STE
Allianz Asset Management GmbH increased its stake in STERIS plc (NYSE:STE) by 16.9% during the third quarter, acquiring an additional 13,553 shares, bringing their total holdings to 93,905 shares valued at $23.24 million. Other institutional investors also adjusted their positions in STERIS. The company reported strong Q results, meeting EPS estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $275.20.
STERIS Q3 Earnings Call Highlights
STERIS (NYSE: STE) reported solid third-quarter fiscal 2026 results with a 9% rise in revenue and diluted EPS, despite ongoing tariff headwinds and inflation impacting gross margins. The company maintained its full-year guidance but indicated that higher tariffs make reaching the high end of the EPS range less likely. Management outlined various mitigation strategies and anticipates a more challenging comparison in the fourth quarter due to a strong prior-year period and expected slowdowns in certain segments.
STERIS plc (NYSE:STE) Q3 2026 Earnings Call Transcript
STERIS plc (NYSE:STE) reported strong third-quarter 2026 results, with total as-reported revenue growing 9% and constant currency organic revenue up 8%, driven by volume and pricing. Despite increased tariffs and inflation impacting gross and EBIT margins, adjusted net income rose to $249.4 million, and diluted EPS increased by 9% to $2.53. The company maintained its fiscal 2026 outlook for revenue and earnings, navigating tariff headwinds and expressing confidence in future growth while actively seeking strategic acquisitions.
Mettler-Toledo stock price target raised to $1,640 by BofA Securities
BofA Securities has increased its price target for Mettler-Toledo (NYSE:MTD) to $1,640 from $1,600, maintaining a Buy rating after the company's Q4 2025 earnings report and conservative 2026 guidance. The firm highlighted Mettler-Toledo's strong execution, prudent outlook, and a "GOOD" financial health score, anticipating low-single-digit growth in China for FY26. Other analysts like Stifel and Bank of America Securities also raised price targets or upgraded ratings, reflecting positive sentiment.
STERIS plc SEC 10-Q Report
STERIS plc has released its latest Form 10-Q report, detailing strong financial and operational performance with significant growth in revenue, profitability, and operational efficiency. The report highlights increased total revenues of $1,496.2 million and net income of $194.3 million, driven by strong demand in its Healthcare and AST segments. The company anticipates continued growth and is focused on enhancing profitability through strategic restructuring and operational improvements.
STERIS: A Bump In The Road For A Reliable Name (NYSE:STE)
STERIS (STE) offers a robust business model with a premium valuation due to its indispensable sterilization networks and consistent healthcare procedure volumes. Despite recent margin pressure from tariffs, resulting in an increased tariff impact guidance, the company achieved its target 8% organic revenue growth. STERIS is poised to benefit from stricter ethylene oxide (EtO) regulations, which will likely lead to outsourcing to larger, established players like itself.
Steris PLC (STE) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Tariff Challenges By GuruFocus
Steris PLC reported a strong Q3 2026 with a 9% increase in total revenue and 8% constant currency organic growth. Despite a decline in gross margin due to tariffs and inflation, earnings per share rose by 9%. The company maintained its fiscal 2026 earnings outlook, though acknowledging that ongoing tariff challenges make achieving the high end of the forecast less likely.
STE Q3 Earnings Meet, Revenues Beat, Stock Dips in Aftermarket Trading
STERIS plc (STE) reported fiscal third-quarter 2026 adjusted earnings per share of $2.53, matching the Zacks Consensus Estimate, while revenues of $1.50 billion surpassed estimates. Despite beating revenue expectations and showing growth across all segments, the stock dipped 3.6% in aftermarket trading due to investor concerns over contracting gross margins. The company maintained its full-year fiscal 2026 financial guidance.
Piper Sandler Maintains Steris PLC(STE.US) With Buy Rating, Maintains Target Price $300
Piper Sandler analyst Jason Bednar has reaffirmed a Buy rating for Steris PLC (STE.US) and maintained its target price at $300. This assessment is based on TipRanks data, which evaluates analyst performance through success rates and average returns over the past year. The information provided is for educational purposes and does not constitute investment advice.
STE Q3 Earnings Meet, Revenues Beat, Stock Dips in Aftermarket Trading
STERIS plc (STE) reported fiscal third-quarter 2026 adjusted earnings per share that matched the Zacks Consensus Estimate, while revenues surpassed it, increasing 9.5% year over year. Despite the revenue beat and growth across all segments, the stock fell in after-market trading due to investor concerns over the contraction in gross margins. The company maintained its financial guidance for fiscal 2026.
Citizens reiterates Market Outperform rating on STERIS stock after Q3 results
Citizens has reaffirmed its Market Outperform rating and a $280.00 price target for STERIS (NYSE:STE) after the company reported its fiscal third-quarter 2026 results. STERIS exceeded top-line expectations and matched bottom-line consensus, demonstrating strong revenue growth and cost discipline despite increased tariff impacts. The firm's robust free cash flow profile and an attractive PEG ratio suggest potential undervaluation and financial strength, positioning it well within the large-cap medical technology sector.
Citizens reiterates Market Outperform rating on STERIS stock after Q3 results
Citizens has reaffirmed its Market Outperform rating and $280.00 price target for STERIS (NYSE:STE) following the medical technology company's fiscal third-quarter 2026 results. STERIS surpassed top-line expectations and matched bottom-line consensus, despite increased tariff headwinds. The firm also reiterated its free cash flow guidance due to strong revenue growth and cost discipline, alongside announcing a quarterly dividend of $0.63 per share.
Citizens reiterates Market Outperform rating on STERIS stock after Q3 results
Citizens has reaffirmed its Market Outperform rating and a $280.00 price target for STERIS (NYSE:STE) after the company's fiscal third-quarter 2026 results. STERIS surpassed top-line expectations and met bottom-line consensus estimates, demonstrating high-single-digit revenue growth and strong cost discipline despite increased tariff headwinds. The company also reiterated its robust free cash flow guidance for fiscal year 2026, reinforcing Citizens' positive outlook.
Needham Maintains Steris PLC(STE.US) With Hold Rating
Needham analyst Michael Matson has maintained a Hold rating on Steris PLC (STE.US). Matson's success rate is 43.3% with an average return of 1.0% over the past year. TipRanks, an independent third party, provides the analysis data for these ratings.
STERIS (NYSE:STE) Beats Q4 CY2025 Sales Expectations
STERIS (NYSE:STE) reported Q4 CY2025 sales of $1.50 billion, exceeding Wall Street's revenue expectations by 1%, with a 9.2% year-on-year growth. The company's non-GAAP profit of $2.53 per share was in line with analyst estimates, and management reiterated its full-year Adjusted EPS guidance. Despite a slight deceleration in projected revenue growth, the company's long-term sales performance and operating margin growth indicate a strong market position.
STERIS plc Reports 9% Revenue Growth in Fiscal 2026 Third Quarter; Maintains Fiscal Outlook
STERIS plc reported a 9% increase in total revenue to $1.5 billion for the third quarter of fiscal 2026, alongside growth in both reported and adjusted earnings per share. The company maintained its fiscal 2026 outlook, projecting 8-9% revenue growth and adjusted EPS of $10.15 to $10.30, despite an anticipated increase in negative tariff impacts. Strong operational performance and robust cash flow generation characterized the quarter.
STERIS (NYSE:STE) Beats Q4 CY2025 Sales Expectations
STERIS (NYSE:STE) reported stronger-than-expected Q4 CY2025 sales, reaching $1.50 billion, a 9.2% year-on-year increase that surpassed analyst estimates. Adjusted earnings per share of $2.53 were in line with consensus. The company reiterated its full-year Adjusted EPS guidance and noted continued revenue growth, though with a slight deceleration projected for the next 12 months.
Earnings Flash (STE) STERIS plc Reports Q3 Revenue $1.5B, vs. FactSet Est of $1.48B
STERIS plc (STE) reported its Q3 revenue reached $1.5 billion, surpassing FactSet's estimated $1.48 billion. This financial update indicates a stronger-than-anticipated performance for the company during the quarter. The news was published on February 4, 2026, at 04:45 pm EST.
Tariffs climb but STERIS still sticks to 2026 profit targets
STERIS (NYSE: STE) reported a 9% year-over-year increase in fiscal 2026 third-quarter revenue to $1.5 billion, with adjusted EPS at $2.53. Despite an increased tariff impact now estimated to reduce pre-tax profit by $55 million, the company maintained its fiscal 2026 outlook for adjusted EPS of $10.15–$10.30 and revenue growth of 8–9%. The company's strong performance was attributed to solid execution, a diversified portfolio, and cost discipline, leading to significant earnings per share growth.
STERIS earnings test: Can procedure volumes fuel another beat? By Investing.com
STERIS plc is reporting its fiscal third-quarter earnings, with analysts anticipating another beat driven by increased procedure volumes from the fourth quarter of 2025. The company has a history of exceeding revenue and EPS forecasts, and investors will be closely watching procedure volumes, capital equipment sales, recurring revenue streams, and performance across its Healthcare, Applied Sterilization Technologies, and Life Sciences divisions. STERIS's strong financial performance and operational leverage set a high bar for this upcoming earnings report.
STERIS earnings test: Can procedure volumes fuel another beat? By Investing.com
STERIS plc is set to report its fiscal third-quarter earnings, with analysts anticipating a continuation of its beat-and-raise pattern, driven by increased procedure volumes from late 2025. The company is expected to report earnings per share of $2.53 and revenue of $1.48 billion, showing an 8% year-over-year growth for revenue. Investors will be observing procedure volumes, the sustainability of capital equipment sales, recurring revenue streams, and the performance across its diverse operating segments.
STERIS earnings test: Can procedure volumes fuel another beat? By Investing.com
STERIS plc is reporting its fiscal third-quarter earnings, with analysts anticipating another beat driven by increased procedure volumes. The company, which specializes in medical equipment sterilization, is expected to show sequential improvement in EPS and continued revenue growth. Investors will be closely watching procedure volumes, capital equipment sales, recurring revenue streams, and the performance of its various operating segments.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Inogen (INGN) is positioned for growth due to strong prospects in the portable oxygen concentrator (POC) market, solid third-quarter 2025 performance, and an expanding product portfolio. Although facing competition and forex volatility, the company projects significant earnings growth for 2026 and has an attractive valuation. The expansion of its product lineup and strategic partnerships are also key growth drivers.
